Difference between revisions of "Dinaciclib (SCH-727965)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
Warner-admin (talk | contribs) m (Text replacement - "Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)" to "Chronic lymphocytic leukemia (CLL/SLL)") |
||
| Line 4: | Line 4: | ||
==Preliminary data== | ==Preliminary data== | ||
| − | ===[[Chronic lymphocytic leukemia (CLL | + | ===[[Chronic lymphocytic leukemia (CLL/SLL)]]=== |
# Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, Hessler J, Grever MR, Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015 Jul;29(7):1524-9. Epub 2015 Feb 24. [http://www.nature.com/leu/journal/v29/n7/full/leu201531a.html link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551390/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25708835 PubMed] | # Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, Hessler J, Grever MR, Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015 Jul;29(7):1524-9. Epub 2015 Feb 24. [http://www.nature.com/leu/journal/v29/n7/full/leu201531a.html link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4551390/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25708835 PubMed] | ||
Revision as of 14:58, 14 October 2017
Mechanism of action
A cyclin dependent kinase inhibitor that selectively inhibits cyclin dependent kinases CDK1, CDK2, CDK5, CDK9, and CDK12.
Preliminary data
Chronic lymphocytic leukemia (CLL/SLL)
- Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, Hessler J, Grever MR, Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia. 2015 Jul;29(7):1524-9. Epub 2015 Feb 24. link to original article link to PMC article PubMed
Multiple myeloma
- Kumar SK, LaPlant B, Chng WJ, Zonder J, Callander N, Fonseca R, Fruth B, Roy V, Erlichman C, Stewart AK. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single agent activity in patients with relapsed multiple myeloma. Blood. 2015 Jan 15;125(3):443-8. Epub 2014 Nov 13. link to original article link to PMC article PubMed